a standard approach with a single intramuscular (IM) dose of fi rst generation Ad serotype 5 expressing beta-galactosidase (AdlacZ) (5×10 10 virus particles (vp)), mice, 1×10 12 vp, Guinea pigs (GP)) 28 days prior to administration of rAd5 expressing Ebola Zaire glycoprotein (ZGP) by the IM, nasal (IN) and sublingual (SL) routes. Since immunity to Ad occurs through the respiratory mucosa, PEI was established in a second group with a single IN dose of AdlacZ (5× 10 vp, mice, 1×10 12 vp, GP) 28 days prior to immunization (IM, IN and SL). A third group was given AdlacZ by both the IM and the IN routes (5×10 10 vp each route, mice) prior to immunization. Multiparameter fl ow cytometry analysis of cells isolated from spleen 10 days after immunization revealed that when PEI is induced by the same route the vaccine is given and by the IM and IN routes in combination, the amount of ZGP-specifi c CD8+ IFN-γ producing T cells in these regions and the percentage of polyfunctional ZGP-specifi c cells simultaneously producing IFN-γ, IL-2 and TNF-α are signifi cantly reduced. The ZGP-specifi c effector/effector memory CD8+ T cell proliferative response followed the same trend for each method. Th2 type ZGP-specifi c antibody responses were signifi cantly reduced in each group and a sharp increase in anti-Ad antibodies noted in serum 28 days after vaccination. This correlated with poor survival after challenge with a lethal dose of rodent-adapted Ebola Zaire. When PEI was induced by a single route different from that used for immunization, the magnitude of the ZGP-specifi c IFN-γ producing CD8+ T cell response was reduced. However, the polyfunctional ZGPspecifi c T cell and antibody responses were not different from that of naïve animals. Survival rates in these groups were higher than when PEI was induced by the same route as immunization. Establishment of PEI by the same route used for immunization is the most stringent model for evaluating the potency of Ad5-based vaccines. Restoration of the quality of the antigen-specifi c CD8+ T cell response and Th-2 type antibody responses are necessary for effective immunization in those with PEI. Data from formulated vaccines that support these conclusions will also be discussed.
Immunotherapy has potential as an effective and sustained therapy for cancer. However, induction of antitumor immunity may not be suffi cient to achieve signifi cant antitumor response. Counteracting the immunological downregulation that protects tumors from the host immune cell attack, could improve therapy outcome. Oncolytic adenovirus is an attractive platform for immunotherapy because virus replication is highly immunogenic and not subject to tolerance. Oncolysis releases tumor epitopes and provides costimulatory danger signals. Arming the virus can improve effi cacy further. CD40 ligand (CD40L, CD154) can induce apoptosis of tumor cells and triggers several immune mechanisms. One of these is a T-helper type 1 (Th1) response, which leads to activation of cytotoxic T-cells and reduction of immune suppression. Here we constructed Ad5/3-hTERT-E1A-hCD40L which features a chimeric Ad5/3 capsid for enhanced tumor transduction, hTERT promoter for tumor selectivity and human CD40L as a therapeutic transgene. We show effective expression of functional CD40L both in vitro and in vivo. Immunogenic cell death mediated by Ad5/3-hTERT-E1A-hCD40L was shown by enhanced levels of calreticulin exposure, as well as HMGB1 and ATP release. Growth of tumors in nude mice was signifi cantly inhibited by oncolysis and apoptosis exerted by Ad5/3-hTERT-E1A-hCD40L. In two syngeneic mouse models, murine CD40L induced recruitment and activation of antigen presenting cells, which increased IL-12 production in splenocytes. This effect was associated with induction of Th1 cytokines interferon-γ, Rantes and tumor necrosis factor-α. Moreover, we noticed enhanced presence of macrophages and cytotoxic CD8+ T cells but not B-cells in tumors treated with Ad5/3-CMV-mCD40L. In summary, adenoviruses coding for CD40L mediate multiple anti-tumor effects including oncolysis, apoptosis, induction of T-cell responses, and upregulation of Th1 cytokines. The prognosis of patients with high-grade glioma remains grim despite improvements in standard therapies including surgery, radiation and chemotherapy. The antigen heterogeneity of malignant gliomas, together with the subset of glioma stem-like initiating cells (GSCs) thought to be responsible for disease progression and recurrence, pose signifi cant challenges for current therapies. Our research program is focused on the development of T cell therapies for malignant glioma targeting IL-13 receptor α2 (IL13Rα2), a cell surface receptor that is over-expressed by a subset of high-grade gliomas, but not expressed at signifi cant levels by normal brain. The prognostic significance of IL13Rα2 is highlighted by our recent work querying publicly available gene expression databases, demonstrating that high expression of IL13Rα2 is associated with increased glioma malignancy grade, and reduced patient survival. Our group has developed an IL13Rα2-targeting immunotherapy platform for high-grade glioma by genetically modifying cytolytic T cells (CTLs) to express an IL13Rα2-specifi c chimeric antigen receptor (CAR) termed IL13-zetakine. This CAR recognizes IL13Rα2 via a membrane-tethered IL13 ligand, and initiates cytolytic killing via an intracellular CD3-zeta domain. We now show that while glioma IL13Rα2 expression varies between patients, for IL13Rα2 pos cases this antigen was detected on both GSCs and more differentiated glioma cells. IL13Rα2-specific CTL were capable of efficient recognition and killing of both IL13Rα2 pos GSC and IL13Rα2 pos differentiated cells in vitro, as well as eliminating glioma initiating activity in an orthotropic mouse tumor model. Further, intracranial administration of IL13-zetakine CTL displayed robust anti-tumor activity against established IL13Rα2 pos GSC tumor sphere-initiated orthotopic tumors in mice. Importantly, our phase I clinical trial employing intracranial adoptive transfer of autologous IL13-zetakine CTL clones demonstrates the feasibility of this approach, absence of serious side effects, and provides evidence for anti-glioma tumor responses for patients with IL13Rα2 positive glioblastomas. For one patient evaluated pre-and post-T cell therapy, IL13-zetakine CTL mediated depletion of the putative CD133 + IL13Rα2 + glioma stem-like population, and recurrence of antigen negative tumor was detected post therapy. This observation supports our preclinical fi ndings that IL13Rα2-specifi c T cells can target IL13Rα2-expressing GSCs, and suggests that IL13Rα2 glioma heterogeneity is a critical challenge for therapeutic success that could possibly be enhanced by identifi cation of additional targets for combination therapy. Taken together, our results provide evidence that adoptive T cell therapy employing IL13Rα2-specifi c CTL is a promising approach and may enhance therapeutic options for patient populations having the poorest prognoses.
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Myeloid High grade gliomas are resistant to current treatment protocols. Immune based therapies have shown promising result in preclinical models but the immunosuppressive environment remains an impediment to the successful transition of such agents to the clinic. Immune suppressive regulatory cells, including myeloid derived suppressor cells (MDSC) are increased in patients with glioma and their reduction can improve immune responses against tumor cells. In this study we characterize the phenotype of MDSC in glioma bearing mice during intra-tumoral immunotherapy with adenovirus secreting murine IL-12p70 (Ad-5/3cRGD.mIL12). We fi nd that GL261 mouse glioma cells can be infected by our vector and secrete mIL12p70 for more than a week. When injected in orthotopic glioma bearing mice Ad-5/3cRGD.mIL12 resulted in increased recruitment and activation of CD4+ and CD8+ T cells, **p<0,01. At the same time we noticed that MDSCs were reduced in Ad-5/3cRGD.mIL12 treated animals, *p<0.05. On the other hand, almost all MDSC were expressing major histocompatibility complex (MHC) class II after IL-12p70 treatment compared to 70% in control treated animals, **p<0.01. Also, the levels of immunosuppressive mediators, ARG-1 and iNOS, were reduced in half. More importantly, this reduction in suppressive mediators and increase in cytotoxic cells during IL12p70 immunotherapy resulted in long-term survival of 60% of the animals. Therefore, in order to design better immunotherapies we have to understand better the delicate equilibrium between suppressor-effector mediators and how to tilt it in our advantage. Ophthalmology and Ocular Oncology, Mayo Clinic, Rochester, MN; 3 Cancer Research UK Cancer Centre, St. James' University Hospital, Leeds, United Kingdom. We reported that expression of a cDNA library of normal human prostate from an immunogenic Vesicular Stomatitis Virus (VSV) platform induced rejection of established murine prostate tumors, without detectable autoimmunity. We now show here that multiple i.v. injections of a cDNA library from human melanoma, expressed from VSV, cured mice bearing melanoma (but not prostate) tumors. To identify the tumor antigens (TA) targeted by this approach, we developed an in vitro screen based upon the ability of LN/splenocytes from VSV-cDNA treated mice to present TA from the VSV-cDNA library upon in vitro infection/stimulation to memory IL-17 CD4+ T cells, which then secreted IL-17 in response to melanoma lysates.
VSV-Expressed cDNA Libraries Cure Established Melanoma and Identify Repertoires of Antigens Which Co-Operate To Stimulate Protective Tumor Immunity
Using this in vitro assay, we isolated single VSV with cDNA inserts from coding sequences of N-RAS, TYRP1 and CYT-C. None of these viruses alone induced B16-specifi c IL-17 recall responses in vitro. However, combination of the N-RAS, TYRP1, CYT-C viruses did induce the IL-17 recall response. Similarly, therapy against B16 tumors was reconstituted in vivo only when the three VSV-N-RAS, VSV-TYRP1 and VSV-CYT-C viruses were used in triple combination. Using depletion assays we have also shown that each of these three antigens are presented to CD4+ T cells through different antigen presenting cell pathways (VSV-N-RAS and VSV-TYRP1 predominantly through CD11b+ macrophages; VSV-CYT-C through Ly6G+ neutrophils and VSV-TYRP1 through CD11c+ plasmacytoid dendritic cells). These data suggest that the cumulative signaling from these types of APC, each expressing specifi c antigens, leads to the activation of the protective Th17 response from CD4+ T cells. We are currently expanding the screen of the melanoma-based VSV-cDNA library to identify additional antigens. Therefore, we describe here a novel technology to defi ne new repertoires of TA which work in combination to generate anti tumor immune responses. We believe that the success of VSV-expressed cDNA libraries is based on 1) the immunogenicity of antigen presentation through viral-associated gene expression; 2) the large number of potential TAA from the cDNA library which can be surveyed by the immune system; and 3) the broad tropism of the virus which allows for delivery in vivo of this large repertoire of potential TAA to a wide range of different types of APC. This technology is readily transferable to the treatment of, and antigen identifi cation in, a variety of other tumor types. Prostate cancer (PCa) is the most common non-skin malignancy and is the second leading cause of cancer death in men. The mortality rate for metastasized PCa is very high. To generate novel and potent treatment for metastasized PCa, our lab has been explore different immunotherapy modalities to generate anti-tumor responses targeting PCa. The current study explores the potential of direct lentivirus vector (LV) injection for eliciting immune responses specifi c for prostate-specifi c antigen (PSA), a tumor-associated antigen used in the diagnosis of PCa. Direct-LV immunization, using a single bicistronic LV that encodes both rhesus (rh) PSA and rhCD25, was tested on: 1) a murine model of PCa, and 2) rhesus macaques. Mice received footpad administration of either LV/eGFP or LV/rhPSA/rhCD25 on day 1 and day 14, followed by tumor challenge on day 21with MOPC-315 or MOPC-315-stably transduced with LV/rhPSA/rhCD25 (rhPSA/rhCD25/MOPC-315). Both MOPC-315 and rhPSA/rhCD25/ MOPC-315 cells generated large tumors in mice immunized with LV/eGFP. On the other hand, only MOPC-315 cells generated large tumors in LV/rhPSA/rhCD25-immunized mice; growth of rhPSA/ rhCD25/MOPC-315 cells was completely inhibited demonstrating a specifi c immune response against the transgene products. To translate this immunotherapy modality to a model more relevant to human application, direct immunization was carried out in rhesus macaque via intranodal LV injection. Four rhesus macaques were immunized bilaterally with intranodal injections of LV/rhPSA/ rhCD25 in the axillary, inguinal, and popliteal lymph nodes and two rhesus macaques were immunized with LV/eGFP as controls. Using magnetic resonance imaging (MRI) we observed that prostates of LV/rhPSA/rhCD25-immunized animals were dramatically enlarged 2 days post-immunization. The prostate sizes were subsequently reduced 2 weeks post-immunization but then demonstrated marked
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